Floatz logo

Autologous, Engineered T Cells Targeting Tp53 R248Q

Pancreas Cancer

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineCell therapyEarly Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
73/ 100

Competitive context

329 Active assets in the Pancreas Cancer cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Chinese PLA General Hospital
Phase 4BBB
Metformin
State University of New York - Downstate Medical Center
Phase 2BBB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
S-1
Liu Xiufeng
Phase 4BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Autologous, Engineered T Cells Targeting Tp53 R248Q is also rated in:

Other Solid TumorDormant
C
Indicative ·
39 / 100
View asset →
lung adenocarcinomaDormant
C
Indicative ·
38 / 100
View asset →
Solid Tumor, AdultDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →